2023
Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin use
2020
Computed Tomographic Angiography Assessment of Epicardial Coronary Vasoreactivity for Early Detection of Doxorubicin-Induced Cardiotoxicity
Feher A, Boutagy NE, Stendahl JC, Hawley C, Guerrera N, Booth CJ, Romito E, Wilson S, Liu C, Sinusas AJ. Computed Tomographic Angiography Assessment of Epicardial Coronary Vasoreactivity for Early Detection of Doxorubicin-Induced Cardiotoxicity. JACC CardioOncology 2020, 2: 207-219. PMID: 34396230, PMCID: PMC8352292, DOI: 10.1016/j.jaccao.2020.05.007.Peer-Reviewed Original ResearchComputed tomography angiographyEpicardial coronary diameterGlobal longitudinal strainCoronary diameterCoronary vasoreactivityLeft ventricular ejection fraction reductionVentricular ejection fraction reductionLongitudinal strainCoronary Computed Tomography AngiographyEjection fraction reductionEpicardial coronary arteriesVentricular ejection fractionDoxorubicin-Induced CardiotoxicityChronic canine modelPrevention of doxorubicinEpicardial vasodilationVasodilator responseAngiography assessmentEjection fractionCumulative dosesCoronary arteryTomography angiographyPharmacological stressorVascular toxicityVascular endothelium
2013
Effect of Escitalopram on Mental Stress–Induced Myocardial Ischemia: Results of the REMIT Trial
Jiang W, Velazquez EJ, Kuchibhatla M, Samad Z, Boyle SH, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O’Connor C. Effect of Escitalopram on Mental Stress–Induced Myocardial Ischemia: Results of the REMIT Trial. JAMA 2013, 309: 2139-2149. PMID: 23695483, PMCID: PMC4378823, DOI: 10.1001/jama.2013.5566.Peer-Reviewed Original ResearchConceptsMental stress-induced myocardial ischemiaStable coronary heart diseaseExercise-induced ischemiaCoronary heart diseaseMyocardial ischemiaHeart diseaseVentricular ejection fraction reductionStress-induced myocardial ischemiaMental stressRegional wall motion abnormalitiesEjection fraction reductionPlacebo-controlled trialST-segment depressionEffect of escitalopramTertiary medical centerWall motion abnormalitiesWeeks of escitalopramSignificant differencesEnd-point assessmentStressor taskEscitalopram groupCardiac eventsEscitalopram treatmentMore patientsTreat analysisPrevalence and Clinical Characteristics of Mental Stress–Induced Myocardial Ischemia in Patients With Coronary Heart Disease
Jiang W, Samad Z, Boyle S, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers J, Kuchibhatla M, O'Connor C, Velazquez EJ. Prevalence and Clinical Characteristics of Mental Stress–Induced Myocardial Ischemia in Patients With Coronary Heart Disease. Journal Of The American College Of Cardiology 2013, 61: 714-722. PMID: 23410543, PMCID: PMC3913125, DOI: 10.1016/j.jacc.2012.11.037.Peer-Reviewed Original ResearchConceptsMental stress-induced ischemiaStress-induced ischemiaCoronary heart diseaseMental stress-induced myocardial ischemiaStable coronary heart diseaseStress-induced myocardial ischemiaExercise-induced ischemiaHeart diseaseMyocardial ischemiaClinical characteristicsHigh riskMental Stress–Induced Myocardial IschemiaExercise-induced myocardial ischemiaVentricular ejection fraction reductionRegional wall motion abnormalitiesEjection fraction reductionST-segment depressionMental stress testWall motion abnormalitiesUnmarried menEligible patientsPoor prognosisMotion abnormalitiesRisk factorsExercise test
2009
Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer
Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer. Clinical Breast Cancer 2009, 9: 101-107. PMID: 19433391, DOI: 10.3816/cbc.2009.n.019.Peer-Reviewed Original ResearchConceptsAdvanced breast cancerCardiac toxicityBreast cancerLiposomal doxorubicinTreatment cyclesCardiac safetyLeft ventricular ejection fraction reductionHER2/neu 2Median progression-free survivalVentricular ejection fraction reductionHER2-positive breast cancerClinical cardiac assessmentCumulative anthracycline dosesEjection fraction reductionNonpegylated Liposomal DoxorubicinGrade 3/4 neutropeniaObjective tumor responseHER2-positive patientsProgression-free survivalPhase I trialClinical cardiac toxicityAnthracycline dosesCytotoxic regimensFebrile neutropeniaTrastuzumab regimen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply